Global Oncolytic Virus Cancer Immunotherapy Market Insights, Forecast to 2028

Oncolytic virus is a special virus that can beneficially infect and kill cancer cells. These are deployed as part of cancer immunotherapy and work by selectively targeting cancer cells and performing oncolytics. Oncolytic viruses can not only kill cancer cells directly, but also stimulate patients' own anti-tumor immune response.

Market Analysis and Insights: Global Oncolytic Virus Cancer Immunotherapy Market

The first oncolytic virus immunotherapy was approved in Latvia in 2004 for the treatment of cutaneous melanoma. Inevitable changes in the environment due to human activities are causing various factors, leading to an increase in the incidence of many skin malignancies, including non-melanoma skin cancer. Conventional radiation and chemotherapy known to treat various cancers, including cutaneous melanoma, have a limited therapeutic index and a range of treatment-related side effects.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Oncolytic Virus Cancer Immunotherapy market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Oncolytic Virus Cancer Immunotherapy market in terms of revenue.

Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Oncolytic Virus Cancer Immunotherapy market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Oncolytic Virus Cancer Immunotherapy market.

Global Oncolytic Virus Cancer Immunotherapy Scope and Market Size

Oncolytic Virus Cancer Immunotherapy market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Oncolytic Virus Cancer Immunotherapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.

Monoclonal Antibodies

Checkpoint Inhibitors

Oncoloytic Viral Therapies and Cancer Vaccines

Lung Cancer

Breast Cancer

Colorectal Cancer

Melanoma

Prostate Cancer

Head and neck Cancer

Ovarian Cancer

Pancreatic Cancer

Others

AstraZeneca

Amgen

F Hoffman-La Roche

Bristol-Myers Squibb

Novartis AG

Merck & Co., Inc.

Pfizer

Biovex

Cell Genesys

Crusade Laboratories

Genelux Corporation

Lokon Pharma

MultiVir

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Type, 2017 VS 2021 VS 2028

1.2.2 Monoclonal Antibodies

1.2.3 Checkpoint Inhibitors

1.2.4 Oncoloytic Viral Therapies and Cancer Vaccines

1.3 Market by Application

1.3.1 Global Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Application, 2017 VS 2021 VS 2028

1.3.2 Lung Cancer

1.3.3 Breast Cancer

1.3.4 Colorectal Cancer

1.3.5 Melanoma

1.3.6 Prostate Cancer

1.3.7 Head and neck Cancer

1.3.8 Ovarian Cancer

1.3.9 Pancreatic Cancer

1.3.10 Others

1.4 Study Objectives

1.5 Years Considered

2.1 Global Oncolytic Virus Cancer Immunotherapy Market Perspective (2017-2028)

2.2 Oncolytic Virus Cancer Immunotherapy Growth Trends by Region

2.2.1 Oncolytic Virus Cancer Immunotherapy Market Size by Region: 2017 VS 2021 VS 2028

2.2.2 Oncolytic Virus Cancer Immunotherapy Historic Market Size by Region (2017-2022)

2.2.3 Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Region (2023-2028)

2.3 Oncolytic Virus Cancer Immunotherapy Market Dynamics

2.3.1 Oncolytic Virus Cancer Immunotherapy Industry Trends

2.3.2 Oncolytic Virus Cancer Immunotherapy Market Drivers

2.3.3 Oncolytic Virus Cancer Immunotherapy Market Challenges

2.3.4 Oncolytic Virus Cancer Immunotherapy Market Restraints

3.1 Global Top Oncolytic Virus Cancer Immunotherapy Players by Revenue

3.1.1 Global Top Oncolytic Virus Cancer Immunotherapy Players by Revenue (2017-2022)

3.1.2 Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Players (2017-2022)

3.2 Global Oncolytic Virus Cancer Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Oncolytic Virus Cancer Immunotherapy Revenue

3.4 Global Oncolytic Virus Cancer Immunotherapy Market Concentration Ratio

3.4.1 Global Oncolytic Virus Cancer Immunotherapy Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Oncolytic Virus Cancer Immunotherapy Revenue in 2021

3.5 Oncolytic Virus Cancer Immunotherapy Key Players Head office and Area Served

3.6 Key Players Oncolytic Virus Cancer Immunotherapy Product Solution and Service

3.7 Date of Enter into Oncolytic Virus Cancer Immunotherapy Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Oncolytic Virus Cancer Immunotherapy Historic Market Size by Type (2017-2022)

4.2 Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Type (2023-2028)

5.1 Global Oncolytic Virus Cancer Immunotherapy Historic Market Size by Application (2017-2022)

5.2 Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Application (2023-2028)

6.1 North America Oncolytic Virus Cancer Immunotherapy Market Size (2017-2028)

6.2 North America Oncolytic Virus Cancer Immunotherapy Market Size by Type

6.2.1 North America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2017-2022)

6.2.2 North America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2023-2028)

6.2.3 North America Oncolytic Virus Cancer Immunotherapy Market Share by Type (2017-2028)

6.3 North America Oncolytic Virus Cancer Immunotherapy Market Size by Application

6.3.1 North America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2017-2022)

6.3.2 North America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2023-2028)

6.3.3 North America Oncolytic Virus Cancer Immunotherapy Market Share by Application (2017-2028)

6.4 North America Oncolytic Virus Cancer Immunotherapy Market Size by Country

6.4.1 North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2017-2022)

6.4.2 North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2023-2028)

6.4.3 U.S.

6.4.4 Canada

7.1 Europe Oncolytic Virus Cancer Immunotherapy Market Size (2017-2028)

7.2 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Type

7.2.1 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Type (2017-2022)

7.2.2 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Type (2023-2028)

7.2.3 Europe Oncolytic Virus Cancer Immunotherapy Market Share by Type (2017-2028)

7.3 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Application

7.3.1 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Application (2017-2022)

7.3.2 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Application (2023-2028)

7.3.3 Europe Oncolytic Virus Cancer Immunotherapy Market Share by Application (2017-2028)

7.4 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country

7.4.1 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2017-2022)

7.4.2 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2023-2028)

7.4.3 Germany

7.4.4 France

7.4.5 U.K.

7.4.6 Italy

7.4.7 Russia

7.4.8 Nordic Countries

8.1 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size (2017-2028)

8.2 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Type

8.2.1 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Type (2017-2022)

8.2.2 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Type (2023-2028)

8.2.3 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Share by Type (2017-2028)

8.3 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Application

8.3.1 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Application (2017-2022)

8.3.2 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Application (2023-2028)

8.3.3 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Share by Application (2017-2028)

8.4 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region

8.4.1 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region (2017-2022)

8.4.2 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region (2023-2028)

8.4.3 China

8.4.4 Japan

8.4.5 South Korea

8.4.6 Southeast Asia

8.4.7 India

8.4.8 Australia

9.1 Latin America Oncolytic Virus Cancer Immunotherapy Market Size (2017-2028)

9.2 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Type

9.2.1 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2017-2022)

9.2.2 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2023-2028)

9.2.3 Latin America Oncolytic Virus Cancer Immunotherapy Market Share by Type (2017-2028)

9.3 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Application

9.3.1 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2017-2022)

9.3.2 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2023-2028)

9.3.3 Latin America Oncolytic Virus Cancer Immunotherapy Market Share by Application (2017-2028)

9.4 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country

9.4.1 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2017-2022)

9.4.2 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2023-2028)

9.4.3 Mexico

9.4.4 Brazil

10.1 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size (2017-2028)

10.2 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Type

10.2.1 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Type (2017-2022)

10.2.2 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Type (2023-2028)

10.2.3 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Share by Type (2017-2028)

10.3 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Application

10.3.1 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Application (2017-2022)

10.3.2 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Application (2023-2028)

10.3.3 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Share by Application (2017-2028)

10.4 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country

10.4.1 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2017-2022)

10.4.2 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2023-2028)

10.4.3 Turkey

10.4.4 Saudi Arabia

10.4.5 UAE

11.1 AstraZeneca

11.1.1 AstraZeneca Company Details

11.1.2 AstraZeneca Business Overview

11.1.3 AstraZeneca Oncolytic Virus Cancer Immunotherapy Introduction

11.1.4 AstraZeneca Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)

11.1.5 AstraZeneca Recent Developments

11.2 Amgen

11.2.1 Amgen Company Details

11.2.2 Amgen Business Overview

11.2.3 Amgen Oncolytic Virus Cancer Immunotherapy Introduction

11.2.4 Amgen Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)

11.2.5 Amgen Recent Developments

11.3 F Hoffman-La Roche

11.3.1 F Hoffman-La Roche Company Details

11.3.2 F Hoffman-La Roche Business Overview

11.3.3 F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Introduction

11.3.4 F Hoffman-La Roche Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)

11.3.5 F Hoffman-La Roche Recent Developments

11.4 Bristol-Myers Squibb

11.4.1 Bristol-Myers Squibb Company Details

11.4.2 Bristol-Myers Squibb Business Overview

11.4.3 Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Introduction

11.4.4 Bristol-Myers Squibb Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)

11.4.5 Bristol-Myers Squibb Recent Developments

11.5 Novartis AG

11.5.1 Novartis AG Company Details

11.5.2 Novartis AG Business Overview

11.5.3 Novartis AG Oncolytic Virus Cancer Immunotherapy Introduction

11.5.4 Novartis AG Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)

11.5.5 Novartis AG Recent Developments

11.6 Merck & Co., Inc.

11.6.1 Merck & Co., Inc. Company Details

11.6.2 Merck & Co., Inc. Business Overview

11.6.3 Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Introduction

11.6.4 Merck & Co., Inc. Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)

11.6.5 Merck & Co., Inc. Recent Developments

11.7 Pfizer

11.7.1 Pfizer Company Details

11.7.2 Pfizer Business Overview

11.7.3 Pfizer Oncolytic Virus Cancer Immunotherapy Introduction

11.7.4 Pfizer Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)

11.7.5 Pfizer Recent Developments

11.8 Biovex

11.8.1 Biovex Company Details

11.8.2 Biovex Business Overview

11.8.3 Biovex Oncolytic Virus Cancer Immunotherapy Introduction

11.8.4 Biovex Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)

11.8.5 Biovex Recent Developments

11.9 Cell Genesys

11.9.1 Cell Genesys Company Details

11.9.2 Cell Genesys Business Overview

11.9.3 Cell Genesys Oncolytic Virus Cancer Immunotherapy Introduction

11.9.4 Cell Genesys Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)

11.9.5 Cell Genesys Recent Developments

11.10 Crusade Laboratories

11.10.1 Crusade Laboratories Company Details

11.10.2 Crusade Laboratories Business Overview

11.10.3 Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Introduction

11.10.4 Crusade Laboratories Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)

11.10.5 Crusade Laboratories Recent Developments

11.11 Genelux Corporation

11.11.1 Genelux Corporation Company Details

11.11.2 Genelux Corporation Business Overview

11.11.3 Genelux Corporation Oncolytic Virus Cancer Immunotherapy Introduction

11.11.4 Genelux Corporation Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)

11.11.5 Genelux Corporation Recent Developments

11.12 Lokon Pharma

11.12.1 Lokon Pharma Company Details

11.12.2 Lokon Pharma Business Overview

11.12.3 Lokon Pharma Oncolytic Virus Cancer Immunotherapy Introduction

11.12.4 Lokon Pharma Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)

11.12.5 Lokon Pharma Recent Developments

11.13 MultiVir

11.13.1 MultiVir Company Details

11.13.2 MultiVir Business Overview

11.13.3 MultiVir Oncolytic Virus Cancer Immunotherapy Introduction

11.13.4 MultiVir Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)

11.13.5 MultiVir Recent Developments

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Author Details

13.3 Disclaimer

List of Tables

    Table 1. Global Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028

    Table 2. Key Players of Monoclonal Antibodies

    Table 3. Key Players of Checkpoint Inhibitors

    Table 4. Key Players of Oncoloytic Viral Therapies and Cancer Vaccines

    Table 5. Global Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028

    Table 6. Global Oncolytic Virus Cancer Immunotherapy Market Size by Region (US$ Million): 2017 VS 2021 VS 2028

    Table 7. Global Oncolytic Virus Cancer Immunotherapy Market Size by Region (2017-2022) & (US$ Million)

    Table 8. Global Oncolytic Virus Cancer Immunotherapy Market Share by Region (2017-2022)

    Table 9. Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Region (2023-2028) & (US$ Million)

    Table 10. Global Oncolytic Virus Cancer Immunotherapy Market Share by Region (2023-2028)

    Table 11. Oncolytic Virus Cancer Immunotherapy Market Trends

    Table 12. Oncolytic Virus Cancer Immunotherapy Market Drivers

    Table 13. Oncolytic Virus Cancer Immunotherapy Market Challenges

    Table 14. Oncolytic Virus Cancer Immunotherapy Market Restraints

    Table 15. Global Oncolytic Virus Cancer Immunotherapy Revenue by Players (2017-2022) & (US$ Million)

    Table 16. Global Oncolytic Virus Cancer Immunotherapy Revenue Share by Players (2017-2022)

    Table 17. Global Top Oncolytic Virus Cancer Immunotherapy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncolytic Virus Cancer Immunotherapy as of 2021)

    Table 18. Ranking of Global Top Oncolytic Virus Cancer Immunotherapy Companies by Revenue (US$ Million) in 2021

    Table 19. Global 5 Largest Players Market Share by Oncolytic Virus Cancer Immunotherapy Revenue (CR5 and HHI) & (2017-2022)

    Table 20. Key Players Headquarters and Area Served

    Table 21. Key Players Oncolytic Virus Cancer Immunotherapy Product Solution and Service

    Table 22. Date of Enter into Oncolytic Virus Cancer Immunotherapy Market

    Table 23. Mergers & Acquisitions, Expansion Plans

    Table 24. Global Oncolytic Virus Cancer Immunotherapy Market Size by Type (2017-2022) & (US$ Million)

    Table 25. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Type (2017-2022)

    Table 26. Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Type (2023-2028) & (US$ Million)

    Table 27. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Type (2023-2028)

    Table 28. Global Oncolytic Virus Cancer Immunotherapy Market Size by Application (2017-2022) & (US$ Million)

    Table 29. Global Oncolytic Virus Cancer Immunotherapy Revenue Share by Application (2017-2022)

    Table 30. Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Application (2023-2028) & (US$ Million)

    Table 31. Global Oncolytic Virus Cancer Immunotherapy Revenue Share by Application (2023-2028)

    Table 32. North America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2017-2022) & (US$ Million)

    Table 33. North America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2023-2028) & (US$ Million)

    Table 34. North America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2017-2022) & (US$ Million)

    Table 35. North America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2023-2028) & (US$ Million)

    Table 36. North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2017-2022) & (US$ Million)

    Table 37. North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2023-2028) & (US$ Million)

    Table 38. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Type (2017-2022) & (US$ Million)

    Table 39. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Type (2023-2028) & (US$ Million)

    Table 40. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Application (2017-2022) & (US$ Million)

    Table 41. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Application (2023-2028) & (US$ Million)

    Table 42. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2017-2022) & (US$ Million)

    Table 43. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2023-2028) & (US$ Million)

    Table 44. Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Type (2017-2022) & (US$ Million)

    Table 45. Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Type (2023-2028) & (US$ Million)

    Table 46. Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Application (2017-2022) & (US$ Million)

    Table 47. Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Application (2023-2028) & (US$ Million)

    Table 48. Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region (2017-2022) & (US$ Million)

    Table 49. Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region (2023-2028) & (US$ Million)

    Table 50. Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2017-2022) & (US$ Million)

    Table 51. Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2023-2028) & (US$ Million)

    Table 52. Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2017-2022) & (US$ Million)

    Table 53. Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2023-2028) & (US$ Million)

    Table 54. Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2017-2022) & (US$ Million)

    Table 55. Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2023-2028) & (US$ Million)

    Table 56. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Size by Type (2017-2022) & (US$ Million)

    Table 57. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Size by Type (2023-2028) & (US$ Million)

    Table 58. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Size by Application (2017-2022) & (US$ Million)

    Table 59. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Size by Application (2023-2028) & (US$ Million)

    Table 60. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2017-2022) & (US$ Million)

    Table 61. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2023-2028) & (US$ Million)

    Table 62. AstraZeneca Company Details

    Table 63. AstraZeneca Business Overview

    Table 64. AstraZeneca Oncolytic Virus Cancer Immunotherapy Product

    Table 65. AstraZeneca Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022) & (US$ Million)

    Table 66. AstraZeneca Recent Developments

    Table 67. Amgen Company Details

    Table 68. Amgen Business Overview

    Table 69. Amgen Oncolytic Virus Cancer Immunotherapy Product

    Table 70. Amgen Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022) & (US$ Million)

    Table 71. Amgen Recent Developments

    Table 72. F Hoffman-La Roche Company Details

    Table 73. F Hoffman-La Roche Business Overview

    Table 74. F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Product

    Table 75. F Hoffman-La Roche Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022) & (US$ Million)

    Table 76. F Hoffman-La Roche Recent Developments

    Table 77. Bristol-Myers Squibb Company Details

    Table 78. Bristol-Myers Squibb Business Overview

    Table 79. Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Product

    Table 80. Bristol-Myers Squibb Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022) & (US$ Million)

    Table 81. Bristol-Myers Squibb Recent Developments

    Table 82. Novartis AG Company Details

    Table 83. Novartis AG Business Overview

    Table 84. Novartis AG Oncolytic Virus Cancer Immunotherapy Product

    Table 85. Novartis AG Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022) & (US$ Million)

    Table 86. Novartis AG Recent Developments

    Table 87. Merck & Co., Inc. Company Details

    Table 88. Merck & Co., Inc. Business Overview

    Table 89. Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Product

    Table 90. Merck & Co., Inc. Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022) & (US$ Million)

    Table 91. Merck & Co., Inc. Recent Developments

    Table 92. Pfizer Company Details

    Table 93. Pfizer Business Overview

    Table 94. Pfizer Oncolytic Virus Cancer Immunotherapy Product

    Table 95. Pfizer Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022) & (US$ Million)

    Table 96. Pfizer Recent Developments

    Table 97. Biovex Company Details

    Table 98. Biovex Business Overview

    Table 99. Biovex Oncolytic Virus Cancer Immunotherapy Product

    Table 100. Biovex Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022) & (US$ Million)

    Table 101. Biovex Recent Developments

    Table 102. Cell Genesys Company Details

    Table 103. Cell Genesys Business Overview

    Table 104. Cell Genesys Oncolytic Virus Cancer Immunotherapy Product

    Table 105. Cell Genesys Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022) & (US$ Million)

    Table 106. Cell Genesys Recent Developments

    Table 107. Crusade Laboratories Company Details

    Table 108. Crusade Laboratories Business Overview

    Table 109. Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Product

    Table 110. Crusade Laboratories Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022) & (US$ Million)

    Table 111. Crusade Laboratories Recent Developments

    Table 112. Genelux Corporation Company Details

    Table 113. Genelux Corporation Business Overview

    Table 114. Genelux Corporation Oncolytic Virus Cancer Immunotherapy Product

    Table 115. Genelux Corporation Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022) & (US$ Million)

    Table 116. Genelux Corporation Recent Developments

    Table 117. Lokon Pharma Company Details

    Table 118. Lokon Pharma Business Overview

    Table 119. Lokon Pharma Oncolytic Virus Cancer Immunotherapy Product

    Table 120. Lokon Pharma Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022) & (US$ Million)

    Table 121. Lokon Pharma Recent Developments

    Table 122. MultiVir Company Details

    Table 123. MultiVir Business Overview

    Table 124. MultiVir Oncolytic Virus Cancer Immunotherapy Product

    Table 125. MultiVir Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022) & (US$ Million)

    Table 126. MultiVir Recent Developments

    Table 127. Research Programs/Design for This Report

    Table 128. Key Data Information from Secondary Sources

    Table 129. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Oncolytic Virus Cancer Immunotherapy Market Share by Type: 2021 VS 2028

    Figure 2. Monoclonal Antibodies Features

    Figure 3. Checkpoint Inhibitors Features

    Figure 4. Oncoloytic Viral Therapies and Cancer Vaccines Features

    Figure 5. Global Oncolytic Virus Cancer Immunotherapy Market Share by Application: 2021 VS 2028

    Figure 6. Lung Cancer Case Studies

    Figure 7. Breast Cancer Case Studies

    Figure 8. Colorectal Cancer Case Studies

    Figure 9. Melanoma Case Studies

    Figure 10. Prostate Cancer Case Studies

    Figure 11. Head and neck Cancer Case Studies

    Figure 12. Ovarian Cancer Case Studies

    Figure 13. Pancreatic Cancer Case Studies

    Figure 14. Others Case Studies

    Figure 15. Oncolytic Virus Cancer Immunotherapy Report Years Considered

    Figure 16. Global Oncolytic Virus Cancer Immunotherapy Market Size (US$ Million), Year-over-Year: 2017-2028

    Figure 17. Global Oncolytic Virus Cancer Immunotherapy Market Size, (US$ Million), 2017 VS 2021 VS 2028

    Figure 18. Global Oncolytic Virus Cancer Immunotherapy Market Share by Region: 2021 VS 2028

    Figure 19. Global Oncolytic Virus Cancer Immunotherapy Market Share by Players in 2021

    Figure 20. Global Top Oncolytic Virus Cancer Immunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncolytic Virus Cancer Immunotherapy as of 2021)

    Figure 21. The Top 10 and 5 Players Market Share by Oncolytic Virus Cancer Immunotherapy Revenue in 2021

    Figure 22. North America Oncolytic Virus Cancer Immunotherapy Market Size YoY (2017-2028) & (US$ Million)

    Figure 23. North America Oncolytic Virus Cancer Immunotherapy Market Size Market Share by Type (2017-2028)

    Figure 24. North America Oncolytic Virus Cancer Immunotherapy Market Size Market Share by Application (2017-2028)

    Figure 25. North America Oncolytic Virus Cancer Immunotherapy Market Size Share by Country (2017-2028)

    Figure 26. United States Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 27. Canada Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 28. Europe Oncolytic Virus Cancer Immunotherapy Market Size YoY (2017-2028) & (US$ Million)

    Figure 29. Europe Oncolytic Virus Cancer Immunotherapy Market Size Market Share by Type (2017-2028)

    Figure 30. Europe Oncolytic Virus Cancer Immunotherapy Market Size Market Share by Application (2017-2028)

    Figure 31. Europe Oncolytic Virus Cancer Immunotherapy Market Size Share by Country (2017-2028)

    Figure 32. Germany Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 33. France Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 34. U.K. Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 35. Italy Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 36. Russia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 37. Nordic Countries Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 38. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size YoY (2017-2028) & (US$ Million)

    Figure 39. Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Size Market Share by Type (2017-2028)

    Figure 40. Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Size Market Share by Application (2017-2028)

    Figure 41. Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Size Share by Region (2017-2028)

    Figure 42. China Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 43. Japan Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 44. South Korea Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 45. Southeast Asia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 46. India Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 47. Australia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

List of Figures

    Figure 48. Latin America Oncolytic Virus Cancer Immunotherapy Market Size YoY (2017-2028) & (US$ Million)

    Figure 49. Latin America Oncolytic Virus Cancer Immunotherapy Market Size Market Share by Type (2017-2028)

    Figure 50. Latin America Oncolytic Virus Cancer Immunotherapy Market Size Market Share by Application (2017-2028)

    Figure 51. Latin America Oncolytic Virus Cancer Immunotherapy Market Size Share by Country (2017-2028)

    Figure 52. Mexico Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 53. Brazil Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 54. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size YoY (2017-2028) & (US$ Million)

    Figure 55. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Size Market Share by Type (2017-2028)

    Figure 56. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Size Market Share by Application (2017-2028)

    Figure 57. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Size Share by Country (2017-2028)

    Figure 58. Turkey Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 59. Saudi Arabia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 60. UAE Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

    Figure 61. AstraZeneca Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)

    Figure 62. Amgen Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)

    Figure 63. F Hoffman-La Roche Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)

    Figure 64. Bristol-Myers Squibb Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)

    Figure 65. Novartis AG Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)

    Figure 66. Merck & Co., Inc. Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)

    Figure 67. Pfizer Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)

    Figure 68. Biovex Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)

    Figure 69. Cell Genesys Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)

    Figure 70. Crusade Laboratories Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)

    Figure 71. Genelux Corporation Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)

    Figure 72. Lokon Pharma Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)

    Figure 73. MultiVir Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)

    Figure 74. Bottom-up and Top-down Approaches for This Report

    Figure 75. Data Triangulation

    Figure 76. Key Executives Interviewed